• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YANG Shan, XU Cheng, YAO Jing. Strategies of nano drug delivery system applied in anti-angiogenic therapy[J]. Journal of China Pharmaceutical University, 2019, 50(1): 11-18. DOI: 10.11665/j.issn.1000-5048.20190102
Citation: YANG Shan, XU Cheng, YAO Jing. Strategies of nano drug delivery system applied in anti-angiogenic therapy[J]. Journal of China Pharmaceutical University, 2019, 50(1): 11-18. DOI: 10.11665/j.issn.1000-5048.20190102
shu

Strategies of nano drug delivery system applied in anti-angiogenic therapy

More Information
    Graphical Abstract
    • Abstract
  • Anti-angiogenic therapy has a wide range of applications in the treatment of tumor. Nano drug delivery system can contribute to higher efficacy and lower toxicity in anti-angiogenic therapy. This article reviews the application of nano drug delivery system in anti-angiogenic therapy and introduces the strategies to improve its treatment efficiency with varieties of nanoparticles, providing reference for the development of anti-angiogenic therapy.
    • FullText(HTML)
    • References (42)
  • [1]
    Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia[J].Cancer Cell,2014,26(5):605-622.
    [2]
    Shi J,Kantoff PW,Wooster R,et al.Cancer nanomedicine:progress,challenges and opportunities[J].Nat Rev Cancer,2016,17(1):20-37.
    [3]
    Folkman J.Tumor angiogenesis:therapeutic implications[J].New Engl J Med,1971,285(21):1182-1186.
    [4]
    Jain RK.Normalizing tumor microenvironment to treat cancer:bench to bedside to biomarkers[J].J Clin Oncol,2013,31(17):2205-2218.
    [5]
    Leung DW,Cachianes G,Kuang WJ,et al.Vascular endothelial growth factor is a secreted angiogenic mitogen[J].Science,1989,246(4935):1306-1309.
    [6]
    Liang X,Xu F,Li X,et al.VEGF signal system:the application of antiangiogenesis[J].Curr Med Chem,2014,21(7):894-910.
    [7]
    Yang S,Gao H.Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy[J].Pharmacol Res,2017,126:97-108.
    [8]
    Lee H,Lee HJ,Bae IJ,et al.Inhibition of STAT3/VEGF/CDK2 axis signaling is critically involved in the antiangiogenic and apoptotic effects of arsenic herbal mixture PROS in non-small lung cancer cells[J].Oncotarget,2017,8(60):101771-101783.
    [9]
    Ferrara N,Adamis AP.Ten years of anti-vascular endothelial growth factor therapy[J].Nat Rev Drug Discov,2016,15(6):385-403.
    [10]
    Jayson GC,Kerbel R,Ellis LM,et al.Antiangiogenic therapy in oncology:current status and future directions[J].Lancet,2016,388(10043):518-529.
    [11]
    Raut CP, Nawrocki S, Lashinger LM, et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts[J].Cancer Biol Ther,2004,3(12):1217-1224.
    [12]
    Wang X, Shen Y, Li S, et al. Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment[J].Int J Mol Med,2016,38(4):1021-1029.
    [13]
    Norrby K.Low-molecular-weight heparins and angiogenesis[J].Apmis,2010,114(2):79-102.
    [14]
    Xu Y,Wen Z,Xu Z.Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism[J].Anticancer Res,2009,29(12):5103-5109.
    [15]
    Lim DK,Wylie RG,Langer R,et al.Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF(165)[J].Biomaterials,2016,77:130-138.
    [16]
    Kim GH,Won JE,Byeon Y,et al.Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer[J].Gynecol Endocrinol,2018,25(1):1-5.
    [17]
    Li Y, Wu Y, Huang L, et al. Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy[J].J Control Release,2016,228:107-119.
    [18]
    Xiong H,Wu YY,Jiang ZJ,et al.pH-activatable polymeric nanodrugs enhanced tumor chemo/antiangiogenic combination therapy through improving targeting drug release[J].J Colloid Interf Sci,2019,536:135-148.
    [19]
    Tian F,Dahmani FZ,Qiao JN,et al.A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer[J].Acta Biomater,2018,75:398-412.
    [20]
    Sun F,Yu Y,Yang Z,et al.Hyaluronic acid-endostatin2-alft1(HA-ES2-AF)nanoparticle-like conjugate for the target treatment of diseases[J].J Control Release,2018,288:1-13.
    [21]
    Ding Y,Ji T,Zhao Y,et al.Improvement of stability and efficacy of C16Y therapeutic peptide via molecular self-assembly into tumor-responsive nanoformulation[J].Mol Cancer Ther,2015,14(10):2390-2400.
    [22]
    Mukherjee P,Bhattacharya R,Wang P,et al.Antiangiogenic properties of gold nanoparticles[J].Clin Cancer Res,2005,11(9):3530-3534.
    [23]
    Gurunathan S,Lee KJ,Kalishwaralal K,et al.Antiangiogenic properties of silver nanoparticles[J].Biomaterials,2009,30(31):6341-6350.
    [24]
    Li X,Wu M,Pan L,et al.Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor[J].Int J Nanomed,2016,11(1):93-105.
    [25]
    Fu X,Yang Y,Li X,et al.RGD peptide-conjugated selenium nanoparticles:antiangiogenesis by suppressing VEGF-VEGFR2-ERK/AKT pathway[J].Nanomedicine,2016,12(6):1627-1639.
    [26]
    Lai PX,Chen CW,Wei SC,et al.Ultrastrong trapping of VEGF by graphene oxide:anti-angiogenesis application[J].Biomaterials,2016,109:12-22.
    [27]
    Balakrishnan S,Bhat FA,Raja SP,et al.Gold nanoparticle-conjugated quercetin inhibits epithelial-mesenchymal transition,angiogenesis and invasiveness via EGFR/VEGFR-2-mediated pathway in breast cancer[J].Cell Prolif,2016,49(6):678-697.
    [28]
    Jiao M,Zhang P,Meng J,et al.Recent advancements in biocompatible inorganic nanoparticles towards biomedical applications[J].Biomater Sci, 2018,6(4):726-745.
    [29]
    Burrows FJ,Thorpe PE.Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature[J].Proc Natl Acad Sci U S A,1993,90(19):8996-9000.
    [30]
    Kunjachan S,Detappe A,Kumar R,et al.Nanoparticle mediated tumor vascular disruption:a novel strategy in radiation therapy[J].Nano Lett,2015,15(11):7488-7496.
    [31]
    Gao W,Li S,Liu Z,et al.Targeting and destroying tumor vasculature with a near-infrared laser-activated "nanobomb" for efficient tumor ablation[J].Biomaterials,2017,139:1-11.
    [32]
    Zhang C,Ni D,Liu Y,et al.Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy[J].Nat Nanotechnol,2017,12(4):378-386.
    [33]
    Malamas AS,Jin E,Gujrati M,et al.DCE-MRI assessing the anti-angiogenic effect of silencing HIF-1α with targeted multifunctional ECO/siRNA nanoparticles[J].Mol Pharm,2016,13(7):2497-2506.
    [34]
    Miao L,Liu Q,Lin CM,et al.Targeting tumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors[J].Cancer Res,2017,77(3):719-731.
    [35]
    Ruan S,He Q,Gao H.Matrix metalloproteinase triggered size-shrinkable gelatin-gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma[J].Nanoscale,2015,7(21):9487-9496.
    [36]
    Huo M,Zhao Y,Satterlee AB,et al.Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment[J].J Control Release,2017,245:81-94.
    [37]
    Yan L,Gao Y,Pierce R,et al.Development of Y-shaped peptide for constructing nanoparticle systems targeting tumor-associated macrophages in vitro and in vivo[J].Mater Res Express,2014,1(2):025007.
    [38]
    Finlay J,Roberts CM,Dong J,et al.Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden[J].Nanomedicine,2015,11(7):1657-1666.
    [39]
    Wang B,Ding Y,Zhao X,et al.Delivery of small interfering RNA against Nogo-B receptor via tumor-acidity responsive nanoparticles for tumor vessel normalization and metastasis suppression[J].Biomaterials,2018,175:110-122.
    [40]
    Kwak G,Jo SD,Kim D,et al.Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles[J].J Control Release,2017,267:203-213.
    [41]
    Wong PP,Bodrug N,Hodivala-Dilke KM.Exploring novel methods for modulating tumor blood vessels in cancer treatment[J].Curr Biol,2016,26(21):R1161-R1166.
    [42]
    Ebos JM,Lee CR,Kerbel RS.Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy[J].Clin Cancer Res,2009,15(16):5020-5025.
    • Related Articles

  • Related Articles

    [1]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [2]LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901
    [3]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [4]YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003
    [5]ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
    [6]LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
    [7]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [8]CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203
    [9]WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303
    [10]TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572.

  • Cited by

    Periodical cited type(0)

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (1333) PDF downloads (1498) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：286205

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return